Encoded Therapeutics reported phase 1/2 data for its Dravet syndrome gene therapy ETX101 showing a 78% reduction in seizures, a result the company said supports its plan to launch a pivotal study next year. The data provide a robust efficacy signal in a severe pediatric epilepsy with high unmet need, strengthening the case for accelerated development. Encoded tied the early clinical outcome to a pathway toward registrational testing, outlining next steps for trial design and regulatory engagement. Industry observers noted the result could influence development strategies for gene therapies targeting rare neurological disorders, including considerations about single‑arm trials, historical controls and durability endpoints. Dravet syndrome is a treatment‑resistant neonatal epilepsy often caused by SCN1A mutations; gene therapy approaches aim to correct or compensate for the underlying genetic defect.